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Esophageal adenocarcinoma is a rare, but increasingly common, cancer.  Since many cases of are 
diagnosed at later stages of disease, the mortality rate is high.  Individuals with Barrett’s esophagus 
are at substantially higher risk of esophageal adenocarcinoma, though the absolute risk of 
progression is low.  Identifying individuals at increased risk of progressing from Barrett’s esophagus 
to esophageal adenocarcinoma could greatly improve outcomes through earlier 
detection.  Inflammatory biomarkers have been used to help predict onset of other cancers, but have 
not previously been assessed for esophageal adenocarcinoma.  In a recent report in Cancer 
Epidemiology, Biomarkers & Prevention, Drs. Sheetal Hardikar, Thomas Vaughan, and colleagues in 
the Public Health Sciences Division found that higher levels of the inflammatory biomarkers C-
reactive protein and interleukin-6 are associated with an increased risk of progression from Barrett’s 
esophagus to esophageal adenocarcinoma. 
There are several ways through which inflammation might contribute to cancer development, such 
as through DNA damage, inhibition of apoptosis, angiogenesis, or promotion of cellular 
proliferation.  Importantly, while cancer-promoting processes might take place at a localized spot, 
they lead to systemic inflammatory responses that can be easily assessed in the blood through 
representative biomarkers such as C-reactive protein and interleukin-6.  As several chronic 
inflammatory conditions in the gastrointestinal tract have previously been associated with cancer, 
these inflammatory biomarkers hold promise as a potential biomarker of progression from Barrett’s 
esophagus to esophageal adenocarcinoma.   
To evaluate this relationship, the authors utilized samples and data from the Seattle Barrett’s 
Esophagus Study (SBES).  This well-characterized prospective cohort study includes serial 
assessments of participants with Barrett’s esophagus for up to 17 years of follow-up.  Blood samples 
from baseline and later were measured for mean C-reactive protein and interleukin-6 levels, and 
individuals who progressed were compared to those who did not.  After adjustment, the authors 
found that mean C-reactive protein levels above the median were associated with an 80% increased 
risk of esophageal adenocarcinoma compared to those with mean values below the  
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median.  Similarly, mean interleukin-6 levels above the median also demonstrated a nearly two-fold 
increase in risk compared to those with mean values below the median. 
These results, said lead author Dr. Hardikar, "suggest that minimally-invasive measurements of 
circulating markers of inflammation, particularly C-reactive protein and interleukin-6, may help 
identify persons at higher risk of progression to cancer from those who are likely to follow a benign 
course."  Being able to stratify patients into different levels of risk would be beneficial, as 
"surveillance and prevention efforts could potentially be targeted to the subset of patients with the 
highest risk, substantially reducing cost, patient anxiety, and potential morbidity" (see 
figure).  Additionally, these inflammation markers have the potential to provide a less-invasive 
alternative to current surveillance methods, which involve periodic endoscopic examinations.  If 
validated, this could enhance surveillance compliance and reduce the number of endoscopy-related 
complications. 
While these results are encouraging, said Hardikar, "further research is needed to evaluate the role 
of inflammation in esophageal adenocarcinoma development among those with Barrett’s esophagus. 
Currently, we are evaluating these markers as part of a panel of demographic, lifestyle and other 
biomarker predictors to develop a population risk model for esophageal adenocarcinoma, which may 
lead to significant improvement in clinical management of Barrett’s esophagus."   
 
Other PHS investigators contributing to this project were Drs. Lynn Onstad, Xiaoling Song, Mario 
Kratz, Garnet Anderson, Patricia Blount, Brian Reid, and Emily White. 
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Image provided by Dr. Sheetal Hardikar. 
Within the primary care setting, blood tests for 
inflammatory biomarkers such as C-reactive protein 
and interleukin-6 could be utilized to identify patients 
with Barrett’s esophagus whose absolute risk of 
progression has increased. Risk reduction strategies 
could then be utilized in this group to lower their risk. 
 
 
